Collectively, these analyses suggest that the microbial and metabolic pathway relationships in the tpos-pdl1t and tpos-um-pdl1t groups differ from those in the tpos-umt group, indicating that these common differential gut microbiota and KEGG pathways may mediate the mechanisms of PD-L1 inhibitor immunotherapy in tumor treatment. This evidence concerns the gene CD274 and neoplasm.